InflaRx

What InflaRx does

InflaRx N.V. is a clinical-stage biopharmaceutical company founded in 2007 in Jena, Germany, and listed on Nasdaq under ticker IFRX since 2017. The company applies its proprietary anti-C5a and anti-C5aR technologies to discover and develop highly potent and specific inhibitors of the complement activation factor C5a and its receptor C5aR, targeting life-threatening and debilitating inflammatory diseases with high unmet medical need. Its lead clinical asset, vilobelimab (brand: GOHIBIC), is a first-in-class intravenously delivered anti-C5a monoclonal antibody that received FDA Emergency Use Authorization in April 2023 for treatment of COVID-19 in hospitalized adults on invasive mechanical ventilation or ECMO. The second key asset, izicopan (INF904), is an orally administered small molecule C5aR1 inhibitor in clinical development for hidradenitis suppurativa, chronic spontaneous urticaria, and — as of May 2026 — ANCA-associated vasculitis and select renal diseases (aHUS, IgA nephropathy, C3 glomerulopathy). A third candidate, IFX002, is part of the pipeline alongside the underlying C5a/C5aR complement platform.

InflaRx operates a classic clinical-stage biotech business model with no fully approved commercial products and no material recurring product revenue. Revenue mechanics are dominated by capital markets: post-IPO equity raises totaling approximately $220M between 2023 and 2026 ($40M April 2023, $30M February 2025, $150M May 2026), supplemented by a modest licensing arrangement with Staidson BioPharma for BDB-001 in China ($2.5M investment plus future royalties). Distribution of GOHIBIC under EUA is handled through authorized pharmaceutical distributors to US hospitals and ICUs. The company employs 101-250 staff across Jena (headquarters), Munich/Martinsried, and Ann Arbor, Michigan, and was led in January 2026 through a strategic restructuring with approximately 30% workforce reduction to prioritize izicopan development and extend cash runway to mid-2027, with management stating sufficient funds to execute planned clinical development through 2029.

Name

InflaRx

Legal name

InflaRx N.V.

Website

https://inflarx.de

Company type

Public

Founded year

2007

Operating status

Operating

Headcount range

101–250 employees

Short description

InflaRx is a clinical-stage biopharmaceutical company developing proprietary anti-C5a and anti-C5aR inhibitors for life-threatening inflammatory diseases; its lead assets are GOHIBIC (vilobelimab, FDA EUA for COVID-19) and izicopan, an oral C5aR1 inhibitor in development for hidradenitis suppurativa, ANCA-associated vasculitis, and renal diseases.

Ownership category

akta.pro rank

Product category

Inflammatory Disease Therapeutics

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Gastroenterology & Hepatology Pharmaceuticals (HLAIAAAI)

akta.pro secondary industries

Immunoglobulins (IVIG/SCIG) (HLAIAHAA), General Gastroenterology (HLAKAEAA)

Keywords

• Complement system inhibitors
• Anti-inflammatory therapeutics
• Monoclonal antibody drugs
• Biopharmaceutical development
• Inflammatory disease treatments

Headquarters

HQ city

Jena

HQ country

Germany

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. GOHIBIC (Vilobelimab) Emergency Use: GOHIBIC received Emergency Use Authorization from FDA in April 2023 for treatment of COVID-19 in hospitalized adults. Revenue generated from product sales to healthcare institutions.
2. Licensing and Royalties (BDB-001/China): Partnership with Staidson BioPharma for BDB-001 in China generates USD 2.5 million investment and potential royalties on future sales.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

InflaRx is a clinical-stage biopharmaceutical company that discovers, develops, and commercializes therapeutics targeting the complement system's C5a and C5aR signaling pathway. Its lead authorized product is GOHIBIC (vilobelimab), an intravenously delivered anti-C5a monoclonal antibody with FDA Emergency Use Authorization for treating COVID-19 in hospitalized adults on mechanical ventilation or ECMO. Its pipeline lead is izicopan (INF904), an oral small molecule C5aR1 inhibitor in development for hidradenitis suppurativa, chronic spontaneous urticaria, ANCA-associated vasculitis, and select renal diseases.

Product overview

InflaRx is a biopharmaceutical company focused on anti-inflammatory therapeutics targeting the complement system. The company's product portfolio centers on two main drug candidates: GOHIBIC (vilobelimab), a first-in-class intravenously delivered anti-C5a monoclonal antibody with FDA Emergency Use Authorization for COVID-19, and izicopan (INF904), an orally administered small molecule C5a receptor inhibitor in clinical development for multiple inflammatory diseases. The company leverages its proprietary complement platform technology to develop treatments for life-threatening or debilitating inflammatory conditions with high unmet medical need.

Differentiator

Problem solved

Functional benefit

Brands

• GOHIBIC: Brand name for vilobelimab, an anti-C5a monoclonal antibody authorized under FDA Emergency Use Authorization for COVID-19 treatment in hospitalized adults.

Products and services

• GOHIBIC (vilobelimab) First-in-class, intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a, for the treatment of COVID-19 in hospitalized adults on invasive mechanical ventilation or ECMO under FDA Emergency Use Authorization; sold to US hospitals and healthcare institutions.
• Izicopan (INF904) Orally administered small molecule inhibitor of the C5a receptor (C5aR1) in clinical development for hidradenitis suppurativa, chronic spontaneous urticaria, ANCA-associated vasculitis, and select complement-mediated renal diseases; designed for differentiated pharmacological properties with potential best-in-class efficacy and safety.
• IFX002 Pipeline candidate in InflaRx's complement-mediated inflammatory disease development program, disclosed alongside vilobelimab and izicopan in the company's R&D pipeline.

Quantifiable outcome

• ≥90% blockade of C5a-induced neutrophil activation achieved over 14-day dosing period with izicopan
• +3 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Staidson BioPharma Inc.coreStrategic or Co-development Partner · 21 December 2022Partnership amended in December 2022 to support regulatory approval process in China for BDB-001, an anti-C5a antibody for COVID-19. InflaRx received USD 2.5 million investment from STS with option for additional funding and will receive royalties on future sales of BDB-001 in China.

Scale indicators9 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• ChemoCentryx (Amgen): Developer of avacopan, the first FDA-approved oral C5aR inhibitor for ANCA-associated vasculitis, acquired by Amgen in 2022. The closest direct competitor to InflaRx's izicopan, targeting the same receptor in overlapping inflammatory indications.
• Alexion (AstraZeneca Rare Disease): Complement franchise leader with Soliris and Ultomiris (C5 inhibitors) for PNH, aHUS, and gMG. Competes in the same complement-mediated inflammatory disease space with established global commercialization and rare-disease infrastructure.
• Apellis Pharmaceuticals: Commercial-stage complement therapeutics company with Empaveli (C3 inhibitor for PNH) and Syfovre (geographic atrophy). Targets complement-mediated diseases through a different but overlapping mechanism, comparable in indication focus.
• Omeros Corporation: Clinical-stage company developing narsoplimab, an anti-MASP-2 antibody targeting the lectin pathway of complement. Small-cap complement therapeutics peer with similar profile of clinical-stage assets and reliance on capital markets.

Emerging players

• BioCryst Pharmaceuticals: Commercial-stage rare-disease company with Orladeyo (hereditary angioedema) and an oral kallikrein inhibitor franchise. Operates in the complement-adjacent inflammation/rare-disease space with similar size and growth profile.

Broad incumbents

• Swedish Orphan Biovitrum (Sobi): European-based rare-disease and specialty biopharma with presence in inflammation and hematology. A relevant board-member connection (former President Europe/MENAR) and broader portfolio targeting complement and inflammatory pathways.
• Amgen: Global biopharmaceutical major that acquired ChemoCentryx and now markets avacopan. Represents both the direct C5aR competition and a potential strategic acquirer given its inflammation/rare-disease franchise build-out.
• AstraZeneca: Owns Alexion's complement franchise (Soliris/Ultomiris) and has commercial infrastructure for rare inflammatory diseases. A natural potential acquirer or partner for InflaRx given overlapping therapeutic area and global reach.
• Takeda Pharmaceutical: Global biopharma with rare-disease and immunology franchises acquired through Shire. Has commercial scale in complement-adjacent indications and a track record of mid-cap biotech acquisitions.
• Novartis: Global biopharma with multiple complement programs and an inflammation/immunology portfolio. Represents a potential strategic acquirer for late-stage C5aR assets and a comparable benchmark for cross-border biopharma valuation.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/inflarx-n-v

Revenue estimate

Valuation estimate

Number of profiles

Profiles20 records

Subsidiaries2 records

Funding overview

Funding rounds11 records

Investors17 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about InflaRx